Sanofi (NASDAQ:SNY) Rating Increased to Strong-Buy at StockNews.com

Sanofi (NASDAQ:SNY) was upgraded by stock analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Friday.

Several other equities research analysts have also commented on SNY. Argus upped their price objective on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Citigroup raised shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Three research analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Trading Down 1.1 %

NASDAQ SNY opened at $57.63 on Friday. Sanofi has a 1 year low of $42.63 and a 1 year high of $58.97. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The company has a market capitalization of $145.96 billion, a PE ratio of 28.96, a P/E/G ratio of 1.62 and a beta of 0.60. The company has a fifty day moving average of $54.34 and a 200 day moving average of $50.48.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.05. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The business had revenue of $10.75 billion during the quarter, compared to analysts’ expectations of $16.86 billion. During the same quarter in the previous year, the firm posted $0.95 EPS. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. Research analysts forecast that Sanofi will post 4.25 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in SNY. POM Investment Strategies LLC purchased a new position in Sanofi in the 2nd quarter valued at about $25,000. Frazier Financial Advisors LLC acquired a new position in shares of Sanofi during the fourth quarter valued at approximately $28,000. Larson Financial Group LLC lifted its position in shares of Sanofi by 480.8% in the first quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock valued at $29,000 after acquiring an additional 500 shares in the last quarter. Register Financial Advisors LLC acquired a new stake in shares of Sanofi in the first quarter worth approximately $29,000. Finally, Johnson Financial Group Inc. purchased a new stake in shares of Sanofi during the fourth quarter worth approximately $31,000. Hedge funds and other institutional investors own 10.04% of the company’s stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.